Method for treating nicotine addiction

• US 5,965,567 A
• Filed: 07/15/1997
• Issued: 10/12/1999
• Est. Priority Date: 07/15/1997
• Status: Expired due to Fees

• Current Assignee: Albany Molecular Research Incorporated, Daniel Archer, David Archer, Eve Archer
• Original Assignee: Albany Medical College (Albany Medical Center), Daniel Archer, David Archer, Eve Archer
• Inventors: Archer, Sydney, Glick, Stanley D.
• Primary Examiner(s): Reamer, James H.
• Application Number:
  US08/892,853
• Time in Patent Office: 819 Days
• Field of Search: 514/282
• US Class Current: 514/282
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137

Abstract

The present invention relates to methods for treating nicotine addiction. The method involves administering to the patient an effective amount of a compound having the formula: ##STR1## wherein R¹ is selected from the group consisting of hydrogen and C1 to C6 alkyl;

R² is selected from the group consisting of hydrogen, methyl, and ethyl;

R³ is selected from the group consisting of hydrogen, methyl, C1 to C6 alkanoyl, C3 to C6 cycloalkanoyl, and pyridinecarbonyl;

Q is a bivalent alkylene moiety; and

Y is selected from the group consisting of a halo-(C2 to C6)-alkenyl moiety having 1 or 2 chlorine or bromine atoms attached to the ethylenic carbon, a cycloalkyl moiety, a cyano moiety, and a cyano-(C3 to C6)-alkenyl moiety

or a pharmaceutically acceptable acid-addition salt thereof.

Claims

1. A method for treating a patient addicted to nicotine, said method comprising:

administering to the patient addicted to nicotine an effective amount of a compound having the formula;

##STR5## wherein R¹ is selected from the group consisting of hydrogen and C1 to C6 alkyl;

R² is selected from the group consisting of hydrogen, methyl, and ethyl;

R³ is selected from the group consisting of hydrogen, methyl, C1 to C6 alkanoyl, C3 to C6 cycloalkanoyl, and pyridinecarbonyl;

Q is a bivalent alkylene moiety; and

Y is selected from the group consisting of a halo-(C2 to C6)-alkenyl moiety having 1 or 2 chlorine or bromine atoms attached to the ethylenic carbon, a cycloalkyl moiety, a cyano moiety, and a cyano-(C3 to C6 )-alkenyl moiety

or a pharmaceutically acceptable salt thereof.

2. A method according to claim 1, wherein Y is cyclopropyl.

3. A method according to claim 2, wherein Q is methylene, R¹ and R² are each methyl, and R³ is hydrogen.

4. A method according to claim 1, wherein Y is a cyano moiety or a cyano-(C3 to C6)-alkenyl moiety.

5. A method according to claim 4, wherein Q is methylene, R¹ and R² are each methyl, and R³ is hydrogen.

6. A method according to claim 1, wherein Y is a --CX¹ ═

CX² X³ moiety, one or two of X¹, X², and X³ are independently selected from the group consisting of bromine and chlorine, and the remaining of X¹, X², and X³ are hydrogen.

7. A method according to claim 6, wherein Q is methylene, R¹ and R² are each methyl, and R³ is hydrogen.

8. A method according to claim 1, wherein the compound is contained in a slow-release microcapsule or suspension formulation.

9. A method according to claim 1, wherein the compound is administered orally.

10. A method according to claim 9, wherein the compound is in a tablet, capsule, granular, dispersible powder, suspension, syrup, or elixir form.

11. A method according to claim 10, wherein the compound is in a tablet or capsule form and is admixed with inert diluent, a granulating agent, a disintegrating agent, a lubricating agent, or combinations thereof.

12. A method according to claim 1, wherein the compound is administered in an amount from about 0.025 to about 0.56 mg/kg of the patient'"'"'s body weight per day.

13. A method according to claim 12, wherein the compound is administered in an amount from about 0.05 to about 0.12 mg/kg of the patient'"'"'s body weight per day.

14. A method according to claim 1, wherein said administering is carried out for at least four days and wherein a maintenance dose is administered on the fourth and subsequent days of treatment, about three-quarters of the maintenance dose is administered on the third day of treatment, about one-half of the maintenance dose is administered on the second day of treatment, and about one-quarter of the maintenance dose is administered on the first day of treatment, wherein the maintenance dose is from about 0.025 to about 0.56 mg/kg of the patient'"'"'s body weight per day.

15. A method according to claim 1, wherein said administering is carried out for at least four days and wherein the compound is administered in an amount from about 0.00625 to about 0.14 mg/kg of the patient'"'"'s body weight per day on the first day of treatment, in an amount from about 0.0125 to about 0.28 mg/kg of the patient'"'"'s body weight per day on the second day of treatment, in an amount from about 0.01875 to about 0.42 mg/kg of the patient'"'"'s body weight per day on the third day of treatment, and in an amount from about 0.025 to about 0.56 mg/kg of the patient'"'"'s body weight per day on the fourth and subsequent days of treatment.

16. A method according to claim 15, further comprising:

administering naltrexone, naloxone, or a mixture thereof to the patient in an amount effective to reduce the compound'"'"'s side effects during one or more of the first, second, third, or fourth days of treatment.

17. A method according to claim 15, wherein the compound is administered in an amount from about 0.0125 to about 0.03 mg/kg of the patient'"'"'s body weight per day on the first day of treatment, in an amount from about 0.025 to about 0.06 mg/kg of the patient'"'"'s body weight per day on the second day of treatment, in an amount from about 0.0375 to about 0.09 mg/kg of the patient'"'"'s body weight per day on the third day of treatment, and in an amount from about 0.05 to about 0.12 mg/kg of the patient'"'"'s body weight per day on the fourth and subsequent days of treatment.

18. A method according to claim 17, further comprising:

administering naltrexone, naloxone, or a mixture thereof to the patient in an amount effective to reduce the compound'"'"'s side effects during one or more of the first, second, third, or fourth days of treatment.

19. A method according to claim 1, further comprising:

administering naltrexone, naloxone, or a mixture thereof to the patient in an amount effective to reduce the compound'"'"'s side effects.

20. A method according to claim 19, wherein naltrexone, naloxone, or a mixture thereof is coadministered with the compound.

21. A method according to claim 19, wherein naltrexone, naloxone, or a mixture thereof is administered in an amount from about 0.07 to about 7 mg/kg of the patient'"'"'s body weight per day.

22. A method according to claim 21, wherein naltrexone, naloxone, or a mixture thereof is administered in an amount from about 0.6 to about 0.8 mg/kg of the patient'"'"'s body weight per day.